Major Depressive Disorder Clinical Trial
Official title:
Transcranial Magnetic Stimulation for Adolescent Depression
Major depression (or MDD) in adolescents is a major public health problem. MDD affects
approximately 15% of adolescents; it is associated with impairment in social, family, and
academic functioning, and it is a major risk factor for suicide - a leading cause of death in
adolescents . Unfortunately, there is a paucity of treatment options for this age group.
Selective serotonin reuptake inhibitors (SSRIs) are the only class of medications approved
for treating MDD in adolescents, but rates of remission following treatment with SSRIs are
only 30 to 45 percent. Cognitive behavior therapy is associated with similar remission rates
and access is limited. Most adolescents will require more than one therapeutic intervention
in order to achieve full symptom control. Collectively, there is overwhelming evidence that
additional treatment options are urgently needed to improve outcomes for teens with MDD. One
novel treatment for adolescent MDD is repetitive transcranial magnetic stimulation (rTMS).
Studies in children have been limited (a total of 23 cases). This is surprising given the
evidence suggesting younger adult subjects with MDD respond better to rTMS (56% response
rate) than older subjects. This limited experience with rTMS for adolescent MDD represents a
substantial gap in the knowledge, recently recognized in publications calling for further
study of rTMS in adolescent depression. Most importantly, the mechanism of action of rTMS in
adolescent MDD is not well understood. The objective of this application is to develop an
understanding of the brain alterations associated with the positive clinical changes that
occur with rTMS in adolescent MDD. Such knowledge will provide the basis for pursuing rTMS
for adolescent MDD as a rational therapeutic technique.
Specific Aim: To compare the effect of rTMS on DLPFC glutamate concentration in adolescent
MDD. The investigators hypothesize an increase (normalization to controls) in DLPFC glutamate
after three weeks of rTMS. Furthermore, the change in glutamate concentration will correlate
with a change in MDD symptoms.
PURPOSE: The purpose of this study is to identify neuroimaging, physiological, and clinical
predictors of response, remission, and recovery to repetitive transcranial magnetic
stimulation in youth with treatment resistant major depressive disorder.
BACKGROUND: Major depressive disorder (MDD) is a major public health problem in adolescents.
Unfortunately, there are no effectively targeted treatment options for this age group.
Current remedies are limited in their effectiveness in youth with response and remission
rates no greater than 60 to 30% respectively and treatment effects are not sustained
throughout the life cycle. Further, ongoing controversies persist regarding the safety of
antidepressants in youth. Current interventions were developed to solely target the symptoms
of rather than the underlying neurobiology. Most importantly, there is no way to accurately
predict an individual patient's response to interventions. Consequently, there is a critical
need for optimally targeted interventions that directly address the relevant pathophysiology
of depression.
Repetitive transcranial magnetic stimulation (rTMS) targeting the left dorsolateral
prefrontal cortex (DLPFC) is effective in adults with depression. rTMS is twice as likely to
result in response (relative risk or RR: 2.35 [95% confidence interval or CI: 1.70-3.25]) and
remission (RR: 2.24 [95% CI: 1.53-3.27] than a sham procedure Evidence in youth is also
encouraging, with a 66% response rate in our pilot data (see Summary of Progress). The DLPFC
plays a critical role in emotional regulation, directly connecting it to depressive
symptomology. Our lab and others have clearly implicated structural and functional deficits
in the DLPFC in youth with MDD. What is not known is what biomarkers best predict response,
remission, and recovery with rTMS in youth with treatment resistant MDD. As response is not
universal, this is a significant gap in our knowledge. Our basic model is that rTMS increases
expression of BDNF, up-regulates activity of endocannabinoids, increases glutamate
concentrations, and increases DLPFC activity - correcting the deficit seen in MDD. These
biologic changes enhance executive control of mood state (see our pilot data in the Summary
of Progress). These positive effects may be moderated by comorbidity (i.e., social phobia)
and genotype (i.e., BDNF). How this model fits with response, remission, and recovery has yet
to be fully tested and this information has the potential to be directly clinically
meaningful. The central aim of the project is to evaluate predictors of rTMS response,
remission, and recovery based on integrated neuroimaging, physiological, and clinical
measures. While not a clinical trial per se (efficacy is not the primary outcome measure), we
will use a non-randomized sham lead in to a single active (rTMS) arm study design as a
framework for biomarker discovery.
To accomplish this goal, we will pursue the following specific aims: The primary aim is to
identify baseline neuroimaging, physiological, and clinical predictors of response to 3 weeks
of rTMS treatment in adolescents with treatment resistant MDD.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |